Edward Nash
Stock Analyst at Canaccord Genuity
(3.56)
# 798
Out of 5,180 analysts
75
Total ratings
46.27%
Success rate
7.27%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CORT Corcept Therapeutics | Maintains: Buy | $100 → $110 | $38.12 | +188.56% | 13 | Mar 26, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $89 → $130 | $78.72 | +65.14% | 2 | Mar 24, 2026 | |
| PLRX Pliant Therapeutics | Maintains: Hold | $4 → $3 | $1.18 | +155.32% | 3 | Mar 13, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $62 | $45.70 | +35.67% | 1 | Feb 19, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.13 | +1,073.71% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $505.34 | +16.16% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $29.92 | +257.62% | 2 | Nov 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $4.55 | +515.38% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $5.48 | +264.96% | 3 | Sep 30, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $29.48 | +110.31% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $47 | $27.66 | +69.92% | 10 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $0.76 | +1,079.40% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.22 | +555.74% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $2.85 | +496.49% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.28 | -39.02% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.48 | +37,699.24% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.11 | +414.34% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $19.30 | +324.87% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $14.73 | +225.87% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $4.23 | +15,266.43% | 1 | Nov 8, 2017 |
Corcept Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $100 → $110
Current: $38.12
Upside: +188.56%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $89 → $130
Current: $78.72
Upside: +65.14%
Pliant Therapeutics
Mar 13, 2026
Maintains: Hold
Price Target: $4 → $3
Current: $1.18
Upside: +155.32%
Kiniksa Pharmaceuticals International,
Feb 19, 2026
Initiates: Buy
Price Target: $62
Current: $45.70
Upside: +35.67%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.13
Upside: +1,073.71%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $505.34
Upside: +16.16%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $29.92
Upside: +257.62%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $4.55
Upside: +515.38%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $5.48
Upside: +264.96%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $29.48
Upside: +110.31%
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $27.66
Upside: +69.92%
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.76
Upside: +1,079.40%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.22
Upside: +555.74%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $2.85
Upside: +496.49%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.28
Upside: -39.02%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.48
Upside: +37,699.24%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.11
Upside: +414.34%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $19.30
Upside: +324.87%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $14.73
Upside: +225.87%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $4.23
Upside: +15,266.43%